Results 101 to 110 of about 210,768 (294)

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

УГНЕТЕНИЕ ПРОТИВООПУХОЛЕВОЙ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ ДЕНДРИТНЫХ КЛЕТОК У БОЛЬНЫХ ЗЛОКАЧЕСТВЕННЫМИ ЛИМФОМАМИ, ОБУСЛОВЛЕННОЕ ИЗМЕНЕННОЙ ЭКСПРЕССИЕЙ ФАКТОРА НЕКРОЗА ОПУХОЛИ АЛЬФА

open access: yes, 2016
Recent research revealed dendritic cells (DCs) to have direct antitumor cytotoxic activity and to inhibit the growth and proliferation of tumor cells in vitro. The aim of the present study was to investigate the association between the cytotoxic activity
I. V. Kryuchkova   +19 more
core   +1 more source

Targeting METTL3 Attenuates Thyroid Inflammatory Injury by Restoring Th17/Treg Balance through a YTHDC2‐m6A‐Dependent KDR/VEGFA Loop

open access: yesAdvanced Science, EarlyView.
METTL3‐mediated m6A modification stabilizes KDR/Kdr mRNA through YTHDC2, amplifying the VEGFA‐KDR feedback loop and disturbing Th17/Treg balance. This pathway promotes persistent inflammation and tissue damage in patients with AIT, and inhibiting the METTL3‐KDR axis effectively disrupts this circuit, alleviating thyroid tissue injury and disease ...
Qingyi Hu   +7 more
wiley   +1 more source

CLINICAL AND IMMUNOLOGICAL EFFICIENCY OF INTERFERON ALPHA_2 AS A PART OF COMPLEX THERAPY OF CHILDREN, SUFFERING FROM THE LINGERING RECURRENT FORMS OF PSEUDOTUBERCULOSIS

open access: yesПедиатрическая фармакология, 2007
The researchers have examined 45 children aged between 3 and 14, suffering from the lingering recurrent forms of pseudotuberculosis. 25 children (55,6%) received some conventional therapy, whereas 20 patients (44,3%) used interferon alpha_2. The practice
V.N. Timchenko   +5 more
doaj   +2 more sources

Light‐Activatable Nitric Oxide Release via Intramolecular Electron Transfer for Tumor Pyroptosis Induction

open access: yesAdvanced Science, EarlyView.
This work proposes a novel strategy to fabricate unimolecular pyroptosis photoinitiators activated by deep‐red light at low light doses. It relies on a photosensitization mechanism to trigger nitric oxide (NO) release from benzisothiadiazole‐based N‐nitrosanilines without modification of nitro moieties, thereby boosting pyroptosis‐mediated ...
Chuangxin Zhang   +4 more
wiley   +1 more source

Activation of interferon regulatory factor-3 via toll-like receptor 3 and immunomodulatory functions detected in A549 lung epithelial cells exposed to misplaced U1-snRNA

open access: yes, 2009
U1-snRNA is an integral part of the U1 ribonucleoprotein pivotal for pre-mRNA splicing. Toll-like receptor (TLR) signaling has recently been associated with immunoregulatory capacities of U1-snRNA.
Pfeilschifter, Josef (Prof. Dr.)   +3 more
core   +1 more source

Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment

open access: yesGut and Liver, 2007
Combination therapy with inteferon-alpha and ribavirin is an approved therapy for patients with chronic hepatitis C. However, even with the use of pegylated interferon, response rates are still poor in many difficult-to-treat groups, especially with ...
doaj   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

open access: yesAdvanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang   +6 more
wiley   +1 more source

TME/NIR Dual‐Responsive Zinc‐Based Targeted Nanoagonist for Multimodal Amplification of STING‐Mediated Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
A multifunctional nanoagonist (cDZ@IP) enables nano‐metabolite–driven multimodal activation of the STING pathway and enhanced immune recognition, achieving potent antitumor immunity and suppressing tumor growth and metastasis. This strategy highlights the rational design of therapeutic metabolites and establishes a new paradigm bridging nanomedicine ...
Kepeng Hu   +17 more
wiley   +1 more source

ESCRT‐Mimetic Nanodegrader Targets STING for Anti‐Inflammatory Therapy

open access: yesAdvanced Science, EarlyView.
A nanoplatform‐enabled targeted protein degradation strategy is presented to regulate aberrant STING signaling. STING‐ATTEC induces selective autophagic degradation of STING via formation of a STING–ATTEC–LC3 ternary complex, while the cationic FA‐LNP+ system enhances LC3 generation and targeted delivery. Together, this synergistic approach efficiently
Fuyuan Zhou   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy